Sudeep Pharma is a technology-driven company that makes excipients and specialty ingredients for the food, nutrition, and pharmaceutical industries. It makes products using its technologies, like encapsulation, spray drying, granulation, trituration, liposomal preparations, and blending. The company sells its products in the US, South America, Europe, the Middle East, Africa, and Asia-Pacific, as well as in other countries.
As of December 31, 2024, it has a total annual capacity of 65,579 MT, making it one of the biggest makers of food-grade iron phosphate. The USFDA has given one of its facilities permission to make mineral-based ingredients. The company is also one of the top exporters of mineral ingredients from India. It is also one of the few companies in the world to have CEP and written confirmation certification for calcium carbonate API in the European Union. It was one of the first companies in India to use liposomal ingredient technology.
ICICI Securities and IIFL Capital Services will be managing the issue. MUFG Intime India will register it. Please verify the Sudeep Pharma IPO allotment status.
For more IPO information, examine Sudeep Pharma's DRHP.
Note: 50% of shares will be unlocked 30 days after allotment, while the rest will be free from lock-in restrictions after 90 days.
The company has worked with more than 1,100 customers around the world, including big names like Pfizer, Intas, Mankind, Merck, Aurobindo, Cadila, Micro Labs, and Danone. It makes a lot of money from repeat customers and has an average relationship with its top clients that lasts more than seven years.
The company has offices in the US, Europe, the UK, and Latin America, and it has third-party stocking partners in about 100 countries. It has three factories in Vadodara, Gujarat, that are fully automated and have many international certifications, such as USFDA, BRC, EXCiPACT, FSSC, WHO-GMP, ISO, HACCP, Kosher, and Halal.
The company also has a separate research and development centre that works on particle engineering, making nutrients more available, extending shelf life, and finding new ways to make products. Its research and development efforts include creating new ingredient technologies and processes that don't use solvents.
On June 24, 2025, Sudeep Pharma sent its Draft Red Herring Prospectus (DRHP) to SEBI. The IPO will be open for subscriptions from November 21 to November 25, 2025. The basis of allotment should be set on November 26, 2025, and the stocks should be listed on the BSE and NSE soon after.
Get the information about the risks and strengths for an in-depth review:
Leading the market with a wide range of products in an industry with high barriers to entry
A well-known global customer base with long-term ties to important customers
Effective R&D creates innovative concepts and better products.
The leadership team possess extensive experience and knowledge in the industry and their specific roles.
The facilities are state-of-the-art, comply with all industry standards, hold worldwide certifications, and have the capacity to expand.
The company has established long-term relationships with Fortune 500 companies and other prominent global customers.
The company is the market leader in an industry characterised by high entry barriers for ingredients and a wide range of products.
Risks
The top 10 customers bring in more than 35% of the company's revenue, which is a concentration risk.
Concentration risk comes from getting more than 60% of your revenue from one segment.
Having many operations in Gujarat makes the business more vulnerable to regional disruptions.
Delays or failures in launching new products could hurt growth and profits.
Acquisitions that don't work out can put a strain on resources and lessen the expected synergies.
Delays in getting approval from the government and regulators could cause problems with operations.
The Grey Market Premium (GMP) for the Sudeep Pharma IPO has not yet been updated. Before making an investment decision, you can check the IPO's live GMP and the subscription status to gauge market sentiment and demand. Furthermore, it is important to carefully review the Sudeep Pharma Draft Red Herring Prospectus (DRHP) for detailed company and issue information before clicking on the "Apply Now" button.
1. What is the Sudeep Pharma IPO date?
The IPO is expected to open on November 21, 2025, and close on November 25, 2025. Live subscription details can be monitored through FinnPick.
2. What is the DRHP filing date of Sudeep Pharma?
Sudeep Pharma filed its Draft Red Herring Prospectus (DRHP) with SEBI on June 24, 2025. DRHP details can be monitored through FinnPick.
3. Where can I verify the live GMP and subscription status?
Live Grey Market Premium (GMP) and IPO subscription status can be checked on platforms like Finnpick at the following links:
4. Do I need a demat account to bid for the Sudeep Pharma IPO?
Yes, a demat account is required to bid for the Sudeep Pharma IPO. Click here to get the ultimate list of the top demat account providers.
